Last reviewed · How we verify

Intravenous albumin — Competitive Intelligence Brief

Intravenous albumin (Intravenous albumin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Colloid volume expander / Plasma protein fraction. Area: Critical Care / Intensive Care Medicine.

phase 3 Colloid volume expander / Plasma protein fraction Critical Care / Intensive Care Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous albumin (Intravenous albumin) — Hamilton Health Sciences Corporation. Intravenous albumin restores intravascular oncotic pressure and improves plasma volume expansion in hypovolemic or critically ill patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intravenous albumin TARGET Intravenous albumin Hamilton Health Sciences Corporation phase 3 Colloid volume expander / Plasma protein fraction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Colloid volume expander / Plasma protein fraction class)

  1. Hamilton Health Sciences Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous albumin — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-albumin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: